CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,034,478 | -43.0% | 265,135 | -29.4% | 0.13% | -34.7% |
| Q2 2023 | $21,096,738 | +906.4% | 375,788 | +710.8% | 0.20% | +818.2% |
| Q1 2023 | $2,096,275 | -7.7% | 46,347 | -17.0% | 0.02% | -12.0% |
| Q4 2022 | $2,271,156 | -89.1% | 55,871 | -82.5% | 0.02% | -89.8% |
| Q3 2022 | $20,841,000 | +103.5% | 318,910 | +89.3% | 0.24% | +106.8% |
| Q2 2022 | $10,239,000 | +10.3% | 168,485 | +13.9% | 0.12% | +40.5% |
| Q1 2022 | $9,285,000 | +1802.7% | 147,917 | +4542.7% | 0.08% | +2000.0% |
| Q4 2020 | $488,000 | +82.8% | 3,186 | -0.0% | 0.00% | +100.0% |
| Q3 2020 | $267,000 | -97.7% | 3,187 | -98.0% | 0.00% | -98.1% |
| Q2 2020 | $11,719,000 | +140.0% | 159,458 | +38.5% | 0.10% | +89.1% |
| Q1 2020 | $4,882,000 | +4.6% | 115,112 | +50.2% | 0.06% | +61.8% |
| Q4 2019 | $4,668,000 | +45.4% | 76,636 | +40.3% | 0.03% | +47.8% |
| Q2 2018 | $3,210,000 | – | 54,631 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |